Galecto Biotech has presented “ground-breaking” data from a phase II study with a candidate it partnered with Bristol-Myers Squibb on back in 2014. The clock is now ticking for BMS, which has to decide whether or not to use an option to buy the Denmark-based biotech.
BY STEFAN SINGH KAILAY Offentliggjort 13.03.17 kl. 15:50
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Since Viagra lost patent on June 24, 2013, generic versions of the drug have made the price drop by a staggering 97 %, according to a new analysis from a Danish pharmacy association. It could save Danish consumers millions per year.
Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.
Novo Nordisk leads the way when it comes to medical treatment of obesity. According to Sydbank analyst Søren Løntoft Hansen, the brand new results from a phase II clinical trial with pipeline jewel semaglutide more than meet FDA’s requirements for obesity drugs.
Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.